Biotechnology
Companies applying molecular biology to develop therapeutics and diagnostics. High-risk/high-reward: valuations tie to clinical trial success, intellectual property and partnerships with big pharma.
| Empresa | Último precio | Cambio de precio | Capitalización bursátil | ||
|---|---|---|---|---|---|
|
|
|
AbbVie Inc
ABBV
|
$282,98 |
-1,1%
|
$500,06 B |
|
|
|
Amgen Inc
AMGN
|
$439,99 |
-0,9%
|
$237,87 B |
|
|
|
Gilead Sciences, Inc
GILD
|
$167,27 |
-1%
|
$207,47 B |
|
|
|
Vertex Pharmaceuticals Inc
VRTX
|
$522,74 |
-2,6%
|
$132,49 B |
|
|
|
Regeneron Pharmaceuticals Inc
REGN
|
$935,45 |
-1,1%
|
$96,77 B |
|
|
|
Moderna Inc
MRNA
|
$200,695 |
+2%
|
$80,13 B |
|
|
|
CSL Ltd
CSL
|
AU$186,475 |
+1%
|
$60,07 B |
|
|
|
argenx SE
ARGX
|
€858,2 |
-0,1%
|
$59,25 B |
|
|
|
Natera Inc
NTRA
|
$291,5 |
+0,7%
|
$42,02 B |